Progeria, a model for accelerated aging exhibited by HIV patients? by Cau, Pierre
Progeria, a model for accelerated aging exhibited by
HIV patients?
Pierre Cau
To cite this version:
Pierre Cau. Progeria, a model for accelerated aging exhibited by HIV patients?. 6th Interna-
tional Symposium on HIV and Emerging Infectious Diseases, Mar 2010, France. 7 (Suppl 1),
pp.I29, 2010. <inserm-00663755>
HAL Id: inserm-00663755
http://www.hal.inserm.fr/inserm-00663755
Submitted on 27 Jan 2012
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
INVITED SPEAKER PRESENTATION Open Access
Progeria, a model for accelerated aging exhibited
by HIV patients?
Pierre Cau
From 16th International Symposium on HIV and Emerging Infectious Diseases
Marseille, France. 24-26 March 2010
Aim
To confirm, among HIV1-infected patients, data from
in vitro studies showing that antiretroviral therapies
(ART) induce an accelerated aging through the same
mechanism than genetic laminopathies (progeria) and «
physiological » aging, i.e. through the synthesis and
persistence of farnesylated prelamin A. The perspective
is to minimize ART side effects using the same drug
combination yet given to treat progeria children in
Marseille.
Materials and methods
A multicentric (Marseille, Nice and Montpellier Hospi-
tals) 3 year-long study will analyse 50 HIV1-infected
patients without any ART (A group), 100 infected
patients receiving ART for at least 12 months (B group)
and 50 age- and sex-matched seronegative control sub-
jects. Infected patients will be submitted to 4 successive
investigations (M0, M12, M24 and M36).
Biological tests are performed in Timone Hospital labs
(Marseille): i/ viral load, PBMC isolation, DNA extrac-
tion, proviral DNA measurement [Virology]; ii/ CD4,
CD8, glycemia, insulinemia, HOMA, total-, LDL- and
HDL-cholesterol, triglycerides [Biochemistry labs from
the 3 Hospitals]; iii/ ART assay [Pharmacokinetics Lab];
iv/ detection (western blot, immunocytochemistry) of
PBMC nuclear, cytosolic and mitochondrial ART tar-
gets: A and B lamins, NF-kB and I-kB (proteasome
activity), CD36 (glycosylation), mitochondrial Hsp70,
ROS production, inner membrane potential, cytochrome
C oxidase subunits 2 and 4 [Cell Biology]; v/ genotyping
the ART targets: prelamin A and B processing proteases,
Golgi SREBP-releasing proteases, mitochondrial deoxy-
nucleoside transporters and proteases involved in
nuclear-encoded protein import; telomere length [Mole-
cular Genetics]. CIC-UPCET collaborated to the proto-
col design, recruits control subjects and is in charge of
data statistical treatment.
Results and discussion
The M0 collection just finished. Mitochondrial data will
be presented.
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